Paper Details

  1. Home
  2. Paper Details

Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.

Author: Birket-SmithE, DupontE, HansenE, MikkelsenB, PakkenbergH, PresthusJ, RautakorpiI, RimanE, RinneU K

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

In a triple-blind trial, 92 patients with Parkinson's disease were randomly assigned to receive either levodopa + benserazide or levodopa + carbidopa. Both treatments were equally effective in reducing Parkinsonian symptoms. However, gastrointestinal side effects and involuntary movements were significantly higher and more severe in patients receiving levodopa + carbidopa.
Paper Details　
Original Abstract of the Article :
92 patients with Parkinson's disease not previously treated with levodopa were considered as eligible for this triple-blind trial. Patients were allocated at random to treatment with either levodopa + benserazide ratio 4:1 (Madopar) or levodopa + carbidopa ratio 10:1 (Sinemet) using dosage schedules...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1600-0404.1976.tb04355.x

データ提供：米国国立医学図書館（NLM）

Sinemet vs. Madopar: A Comparative Study of Parkinson's Disease Treatment

Parkinson's disease, a neurodegenerative disorder that affects movement, continues to be a challenge for medical researchers. This study investigates the effectiveness of two commonly used medications, Sinemet and Madopar, in managing Parkinson's symptoms. It's like exploring a vast desert landscape, searching for the most effective paths to ease the burden of this debilitating disease.

A Comparison of Strategies: Sinemet and Madopar

The study found that both Sinemet and Madopar were equally effective in reducing Parkinsonian symptoms. However, Sinemet was associated with a higher frequency and severity of gastrointestinal side effects and involuntary movements. It's like comparing two desert trails, each offering different challenges and rewards. While both trails lead to the same destination, one may be more comfortable and less demanding than the other.

Finding the Right Path

This study highlights the importance of carefully considering the potential side effects of medication when treating Parkinson's disease. While both Sinemet and Madopar are effective in reducing symptoms, the higher incidence of side effects with Sinemet may lead clinicians to favor Madopar for some patients. It's a reminder that the desert of Parkinson's treatment is complex and requires a personalized approach that takes into account individual patient needs and preferences.

Dr. Camel's Conclusion

This study provides valuable insights into the effectiveness and side effects of two commonly used medications for Parkinson's disease. While both Sinemet and Madopar offer symptom relief, the study highlights the importance of considering individual patient needs and carefully weighing the potential benefits and risks of each medication. It's a reminder that the desert of Parkinson's treatment is vast and complex, requiring a personalized approach and ongoing research to find the most effective and tolerable therapies.

Date :
  1. Date Completed 1976-07-06
  2. Date Revised 2019-08-14
Further Info :

Pubmed ID

1266576

DOI: Digital Object Identifier

10.1111/j.1600-0404.1976.tb04355.x

Related Literature

Article Analysis
・Side Effects of levodopa and carbidopa
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.